Valor20202021202220232024TTMDespesas comerciais, gerais e administrativas747 M818 M828 M926 M1.1 B—Pesquisa e desenvolvimento226 M230 M236 M274 M320 M—Lucro operacional332 M389 M695 M813 M842 M—Lucro não operacional, total——————Despesa com juros, líquida de juros capitalizados——————Receitas não operacionais, líquidas das despesas com juros——————Receitas/despesas incomuns——————Lucro antes dos impostos361 M426 M734 M862 M900 M—Participação no lucro——————Impostos125 M115 M186 M194 M229 M—Participação de minoritários————8 M—Outras receitas/despesas após impostos——————Lucro líquido antes das operações descontinuadas236 M311 M548 M668 M671 M—Operações descontinuadas——————Lucro líquido236 M311 M548 M668 M671 M—Ajuste de diluição——————Dividendos de ações preferenciais——————Lucro líquido diluído disponível aos acionistas——————Lucro básico por ação——————Lucro diluído por ação——————Número médio de ações básicas——————Ações diluídas——————EBITDA——————EBIT1.52 B1.71 B1.99 B2.2 B2.42 B—Custo da receita1.19 B1.32 B1.3 B1.39 B1.58 B—Outros componentes do custo——————Amortização e depreciação (fluxo de caixa)——————
Dr. Reddy's Laboratories Ltd
Dr. Reddy's Laboratories Ltd. is an Indian multinational pharmaceutical company based in Hyderabad, with U.S. headquarters in East Brunswick, New Jersey. The company was founded by Kallam Anji Reddy, who previously worked in the mentor institute Indian Drugs and Pharmaceuticals Limited. Dr. Reddy manufactures and markets a wide range of pharmaceuticals in India and overseas. The company produces over 190 medications, 60 active pharmaceutical ingredients for drug manufacture, diagnostic kits, critical care, and biotechnology.
Dr. Reddy's began as a supplier to Indian drug manufacturers, but it soon started exporting to less-regulated markets that had the advantage of not having to spend time and money on a manufacturing plant that would gain approval from a drug licensing body such as the U.S. Food and Drug Administration. By the early 1990s, the expanded scale and profitability from these unregulated markets enabled the company to begin focusing on getting approval from drug regulators for their formulations and bulk drug manufacturing plants – in more-developed economies. This allowed their movement into regulated markets such as the US and Europe.
By 2007, Dr.